Abstract | BACKGROUND: To the authors' knowledge, there currently is no standard therapy for platinum-resistant ependymoma; hence, a need exists for new therapies. In the current study, a retrospective evaluation of temozolomide (TMZ) in adults with recurrent, supratentorial, platinum-refractory, World Health Organization grade 2 ependymoma was performed, with an objective of determining 6-month progression-free survival (PFS). METHODS: A total of 25 patients, ages 28 to 63 years, with recurrent ependymoma were treated. All patients had previously been treated with surgery, radiotherapy, and platinum-based chemotherapy ( cisplatin in 15 patients and carboplatin in 10 patients). Nine patients underwent repeat surgery. Patients were treated at the time of second recurrence with TMZ (5 consecutive days), once every 4 weeks, which was defined as a single cycle. Neurologic evaluation was performed every 4 weeks and neuroradiographic assessment every 8 weeks. RESULTS: A total of 68 cycles of TMZ (median, 2 cycles; range, 1-6 cycles) was administered. TMZ-related toxicity included leukopenia (7 patients; 1 with grade 3 [grade was determine according to National Cancer Institute Common Toxicity Criteria [version 3.0]), constipation (6 patients; none with grade 3), fatigue (5 patients; none with grade 3), anemia (2; none with grade 3), thrombocytopenia (2; none with grade 3), and deep vein thrombosis (2; none with grade 3). One patient (4%) demonstrated a partial radiographic response, 9 (36%) had stable disease, and 15 (60%) developed progressive disease after 2 cycles of TMZ. Time to tumor progression ranged from 1 to 7 months (median, 2 months). Survival ranged from 2 to 8 months (median, 3 months). The 6-month and 12-month PFS were 2% and 0%, respectively. CONCLUSIONS: TMZ in this dose schedule demonstrated little efficacy in a cohort of adults with recurrent, intracranial, platinum-refractory ependymoma.
|
Authors | Marc C Chamberlain, Sandra K Johnston |
Journal | Cancer
(Cancer)
Vol. 115
Issue 20
Pg. 4775-82
(Oct 15 2009)
ISSN: 0008-543X [Print] United States |
PMID | 19569246
(Publication Type: Journal Article)
|
Copyright | Copyright (c) 2009 American Cancer Society. |
Chemical References |
- Antineoplastic Agents, Alkylating
- Ferrous Compounds
- Metallocenes
- EX 10-478
- Dacarbazine
- Carboplatin
- Cisplatin
- Temozolomide
|
Topics |
- Adult
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Carboplatin
(therapeutic use)
- Cisplatin
(therapeutic use)
- Dacarbazine
(adverse effects, analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Ependymoma
(drug therapy)
- Female
- Ferrous Compounds
- Humans
- Male
- Metallocenes
- Middle Aged
- Neoplasm Recurrence, Local
- Retreatment
- Supratentorial Neoplasms
(drug therapy)
- Temozolomide
|